RGC
Regencell BioscienceยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Movement Reasons
Positive FDA Approval
On December 22, 2025, the company announced that the FDA had approved MYQORZO, a treatment for adults with obstructive hypertrophic cardiomyopathy. This approval likely led to increased investor confidence in the company's potential for growth and profitability.
Institutional Investor Interest
Geode Capital Management significantly increased its stake in Regencell Bioscience, growing by 5,637.5% to 391,066 shares, valued at approximately $6.66 million. This increase in institutional investment can be a bullish signal, indicating confidence in the company's future prospects.
Discover more stocks
The above data and information are generated by AI and are for reference only. They do not constitute any investment advice.
